Literature DB >> 6982903

Histocompatibility antigens in progressive systemic sclerosis (PSS; scleroderma).

C J Lynch, G Singh, T L Whiteside, G P Rodnan, T A Medsger, B S Rabin.   

Abstract

Patients with progressive systemic sclerosis (PSS; scleroderma) were typed for the HLA-A, -B, and -DR antigens. No significant differences in the frequencies of any HLA-A or -B antigen were found. In the subgroup of patients with PSS and diffuse scleroderma (PSS-DS), the frequency of Bw35 was increased (0.30 vs 0.17 in controls; p less than 0.005, corrected P greater than 0.2). Although patients with PSS-DS also had an increased frequency of DR1 antigen (0.27 vs 0.12 in local controls; P less than 0.005, corrected P less than 0.05), no association between Bw35 and DR1 antigens could be detected. We found no increase in the frequencies of the DR3 or DR5 antigens in patients with PSS. However, in a subset of PSS patients with pulmonary fibrosis, an increase in DR3 and a decrease in DR4 antigens (P less than 0.005) were observed. Serum antibodies to centromere occurred more frequently in DR1-positive than DR/-negative patients (0.46 vs 0.18; P less than 0.005). This study of a large number of patients with PSS failed to confirm previously reported associations of PSS with the HLA-B8/DR3 haplotype of HLA-DR5 antigen.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6982903     DOI: 10.1007/BF00915073

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  19 in total

Review 1.  The major histocompatibility complex - genetics and biology (third of three parts).

Authors:  F H Bach; J J van Rood
Journal:  N Engl J Med       Date:  1976-10-21       Impact factor: 91.245

2.  Sjögren's syndrome in progressive systemic sclerosis.

Authors:  J F Cipoletti; R B Buckingham; E L Barnes; R L Peel; K Mahmood; F E Cignetti; J M Pierce; B S Rabin; G P Rodnan
Journal:  Ann Intern Med       Date:  1977-11       Impact factor: 25.391

Review 3.  Protein clinical manifestations of primary tumors of the heart.

Authors:  H O McDevitt; W F Bodmer
Journal:  Am J Med       Date:  1972-01       Impact factor: 4.965

4.  HLA-SD antigens in progressive systemic sclerosis.

Authors:  M Giordano; D Magrí; G Valentini; G Tirri; R De Biasi
Journal:  Arch Dermatol Res       Date:  1979-10       Impact factor: 3.017

5.  HLA and scleroderma.

Authors:  A Májský; M Kobíková; Z Stáva
Journal:  Tissue Antigens       Date:  1979-10

6.  Increased frequency of HLA-DR5 in scleroderma.

Authors:  D D Gladman; E C Keystone; M Baron; P Lee; D Cane; H Mervert
Journal:  Arthritis Rheum       Date:  1981-06

7.  Increased frequency of B8/DR3 in scleroderma and association of the haplotype with impaired cellular immune response.

Authors:  C G Kallenberg; J M Van der Voort-Beelen; J D'Amaro; T H The
Journal:  Clin Exp Immunol       Date:  1981-03       Impact factor: 4.330

8.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

Authors: 
Journal:  Arthritis Rheum       Date:  1980-05

9.  Association of the B-cell alloantigen DRw4 with rheumatoid arthritis.

Authors:  P Stastny
Journal:  N Engl J Med       Date:  1978-04-20       Impact factor: 91.245

10.  HLA-D antigens in progressive systemic sclerosis (scleroderma).

Authors:  A G DiBartolomeo; B S Rabin; G P Rodnan
Journal:  Immunol Commun       Date:  1981
View more
  8 in total

Review 1.  Epidemiology of scleroderma.

Authors:  A J Silman
Journal:  Ann Rheum Dis       Date:  1991-11       Impact factor: 19.103

Review 2.  Major histocompatibility complex class II genes and systemic sclerosis.

Authors:  D Briggs; K I Welsh
Journal:  Ann Rheum Dis       Date:  1991-11       Impact factor: 19.103

3.  Antinuclear antibodies in the relatives and spouses of patients with systemic sclerosis.

Authors:  P J Maddison; R P Skinner; R S Pereira; C M Black; B M Ansell; M I Jayson; N R Rowell; K I Welsh
Journal:  Ann Rheum Dis       Date:  1986-10       Impact factor: 19.103

4.  Association of polar amino acids at position 26 of the HLA-DQB1 first domain with the anticentromere autoantibody response in systemic sclerosis (scleroderma).

Authors:  J D Reveille; D Owerbach; R Goldstein; R Moreda; R A Isern; F C Arnett
Journal:  J Clin Invest       Date:  1992-04       Impact factor: 14.808

5.  Antinuclear antibodies in patients with scleroderma (systemic sclerosis) and in their blood relatives and spouses.

Authors:  A J Barnett; L J McNeilage
Journal:  Ann Rheum Dis       Date:  1993-05       Impact factor: 19.103

6.  The HLA-DR and DQ genes control the autoimmune response to DNA topoisomerase I in systemic sclerosis (scleroderma).

Authors:  M Kuwana; J Kaburaki; Y Okano; H Inoko; K Tsuji
Journal:  J Clin Invest       Date:  1993-09       Impact factor: 14.808

7.  Association of amino acid sequences in the HLA-DQB1 first domain with antitopoisomerase I autoantibody response in scleroderma (progressive systemic sclerosis).

Authors:  J D Reveille; E Durban; M J MacLeod-St Clair; R Goldstein; R Moreda; R D Altman; F C Arnett
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

8.  T lymphocyte subset abnormalities and HLA antigens in scleroderma (systemic sclerosis).

Authors:  A J Barnett; B D Tait; M A Barnett; B H Toh
Journal:  Clin Exp Immunol       Date:  1989-04       Impact factor: 4.330

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.